Join Dr. Zi Li, Associate Director of Formulation at BioDuro, to explore how polymorph screening, salt formation and cocrystallisation can resolve dissolution, stability and IP challenges in early-stage drug development.
The same pharmaceutical compound can exist in multiple crystalline forms - each with distinct properties that directly affect dissolution, stability, processability and intellectual property strategy.
This makes solid-state selection a critical decision in early-stage drug development.
When key API properties fall short of development requirements, solid form optimisation - including polymorph screening, salt formation and cocrystallisation - can modify behaviour without altering the underlying chemical structure. Different crystal forms of the same API can also exhibit distinct properties that support separate patent protection, making crystal form an important pillar of IP strategy.
Overall, a comprehensive understanding of solid form landscapes is essential in pharmaceutical development. On June 10, our Associate Director of Formulation, Dr. Zi Li, will present key aspects of crystalline forms in drug development, share case studies on how solid form optimization can modify drug properties, and discuss preformulation strategies to accelerate preclinical formulation workflows.
Everything you need to know:
- Understand how polymorphs, salts and cocrystals influence drug performance and formulation viability
- Explore how solid form optimisation can resolve dissolution, stability and processability challenges without changing the underlying molecule
- Learn how crystal form selection supports patent protection and wider intellectual property strategy
- See case studies demonstrating how targeted solid form optimisation has modified API behaviour in practice
- Discover how preformulation studies can accelerate preclinical formulation workflows and de-risk later-stage development
Is the panel discussion free?
Yes – there is no charge to watch the panel discussion, either live or on-demand. Simply become a member today.
When will the panel discussion take place?
10 June 2026 at PM BST
Can I watch it later?
The panel discussion will become available to watch on-demand shortly after the live webinar takes place.
What are the benefits of attending live?
You’ll be able to ask the speakers your questions, which will be answered live in the Q&A towards the end of the session.
How long will the panel discussion be?
This panel discussion will last up to an hour.
What do I need to watch this panel discussion?
All you need is a computer with an internet connection. We recommend using headphones if possible if you’re in an office environment.
Our Speaker
Zi Li - Associate Director, Formulation, BioDuro
Dr. Zi Li is Associate Director of Formulation at BioDuro, where she leads studies in solid-state optimization, supporting polymorph, salt, and cocrystal screening for global clients.
Dr. Li has over a decade of experience in organic small-molecule crystallization. She holds a Ph.D. in Chemistry from University of Michigan with a research focus on dissolution behaviours of multicomponent crystalline systems.
She has worked in industrial pharmaceutical R&D since 2018, gaining extensive experience in both academic and industrial solid form optimization and the development of crystallization methodologies.
